IPO - Profile


We are a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which we are able to genetically select patients we believe will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. We have in-licensed product candidates, each with a differentiated profile relative to available therapies, and we intend to continue strengthening our pipeline through focused business development and internal research efforts. Our lead product candidate, RAIN-32 (milademetan, formerly known as DS-3032), is a small More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$17.00 7,350,000 Positive High 60.12%

Offering Team

  • Legal counsel
  • Gibson, Dunn & Crutcher LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 19 Apr, 2021

Offer 23 Apr, 2021

Look Ahead

Lock Up Expiry Oct 23, 2021

IPO Terms

Offer Price $17.00
Offer Size 7M

Market Sentiments

Stock Price